WEBULL

GH Research (GHRS) Is Up 24.2% After FDA Lifts Hold On GH001 U.S. Trial Enrollment

Simply Wall St · 3d ago
  • GH Research PLC recently reported that the U.S. FDA has lifted the clinical hold on its GH001 IND, allowing U.S. subject enrollment after Phase 2b data in treatment‑resistant depression showed rapid remission, brief psychoactive effects, and a favorable safety profile without psychotherapy.
  • The combination of ultra-rapid symptom relief, discharge-readiness within about an hour, and infrequent dosing positions GH001 as a potentially practical fit for interventional psychiatry clinics.
  • We’ll now examine how the FDA’s decision to lift the clinical hold and enable U.S. enrollment shapes GH Research’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is GH Research's Investment Narrative?

To own GH Research, you need to believe that GH001’s Phase 2b profile can translate into a scalable, regulator‑approved treatment for hard‑to‑treat mood disorders, without the operational complexity of psychedelic‑assisted therapy. The FDA’s decision to lift the clinical hold is a meaningful shift in the near term, because it re‑opens the U.S. path and turns upcoming U.S. enrollment, regulatory feedback and trial design clarity into the key catalysts to watch, rather than just non‑U.S. data readouts. At the same time, the core risks have not disappeared: GH Research is still pre‑revenue, loss‑making and reliant on capital markets, and any future safety, efficacy or regulatory setbacks could quickly challenge the recent share price strength and current optimism.

However, investors should be aware of how GH Research’s cash burn and lack of revenue could intersect with future trial needs. The analysis detailed in our GH Research valuation report hints at an inflated share price compared to its estimated value.

Exploring Other Perspectives

GHRS 1-Year Stock Price Chart
GHRS 1-Year Stock Price Chart
Across two Simply Wall St Community fair value estimates, views range from just above US$3 to above US$30, underscoring how far apart individual expectations sit. Set against that, the newly lifted FDA hold and U.S. trial plans put clinical execution and future funding firmly in focus, which could be just as important for GH Research’s long term outcome as any valuation model.

Explore 2 other fair value estimates on GH Research - why the stock might be worth less than half the current price!

Build Your Own GH Research Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your GH Research research is our analysis highlighting 3 important warning signs that could impact your investment decision.
  • Our free GH Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GH Research's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.